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Abstract: The group of pattern recognition receptors includes families of Toll-like receptors, 
NOD-like receptors, C-type lectin receptors, and RIG-I-like receptors. They are key sensors for a 
number of infectious agents, some of which are oncogenic, and they launch an immune response 
against them, normally promoting their eradication. Inherited variations in genes encoding these 
receptors and proteins and their signaling pathways may affect their function, possibly modulat-
ing cancer risk and features of cancer progression. There are numerous studies investigating 
the association of single nucleotide polymorphisms within or near genes encoding Toll-like 
receptors and NOD-like receptors, cancer risk, and features of cancer progression. However, 
there is an almost total absence of articles analyzing the correlation between polymorphisms of 
genes encoding C-type lectin receptors and RIG-I-like receptors and cancer risk or progression. 
Nevertheless, there is some evidence supporting the hypothesis that inherited C-type lectin recep-
tor and RIG-I-like receptor variants can be associated with increased cancer risk. Certain C-type 
lectin receptors and RIG-I-like receptors recognize pathogen-associated molecular patterns of 
potentially oncogenic infectious agents, and certain polymorphisms of genes encoding C-type 
lectin receptors and RIG-I-like receptors may have functional consequences at the molecular 
level that can lead to association of such single nucleotide polymorphisms with risk or progres-
sion of some diseases that may modulate cancer risk, so these gene polymorphisms may affect 
cancer risk indirectly. Polymorphisms of genes encoding C-type lectin receptors and RIG-I-like 
receptors thereby may be correlated with a risk of lung, oral, esophageal, gastric, colorectal, 
and liver cancer, as well as nasopharyngeal carcinoma, glioblastoma, multiple myeloma, and 
lymphoma. The list of the most promising polymorphisms for oncogenomic investigations 
may include rs1926736, rs2478577, rs2437257, rs691005, rs2287886, rs735239, rs4804803, 
rs16910526, rs36055726, rs11795404, and rs10813831.
Keywords: C-type lectin receptors, RIG-I-like receptors, cancer, single nucleotide polymor-
phisms, genetic variation, inflammation
Brief description of pattern recognition receptors
Pattern recognition receptors directly recognize common antigen determinants of vir-
tually all classes of pathogens (so-called pathogen-associated molecular patterns, or 
PAMPs).1–4 In addition, they recognize endogenous ligands, usually releasing during 
cell stress and known as damage-associated molecular patterns.1–4 As a result of ligand 
recognition, pattern recognition receptors initiate an immune response via specific 
intracellular signaling pathways, and so have a key role in initiation and promotion of 
septic and aseptic inflammation.1–4 Pattern recognition receptors also have a number of 
other vital functions apart from participation in the immune response, in that they may 
regulate many aspects of cell proliferation, survival, apoptosis, autophagy,   generation 
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of reactive oxygen species, pyroptosis, angiogenesis, and, con-
sequently, tissue remodeling and repair.1–4 There are four main 
groups of pattern recognition receptors, ie, Toll-like receptors, 
NOD-like receptors, C-type lectin receptors, and RIG-I-like 
receptors, and genes encoding them are broadly expressed, eg, 
in epithelial cells, endothelial cells, keratinocytes, lympho-
cytes, granulocytes, fibroblasts, and neurons.1–4 A summary 
of the most modern conceptual data about members of these 
groups and about their structure and function can be obtained 
from recent comprehensive reviews by Kawai and Akira,1 
Elinav et al,2 Osorio et al,3 and Loo and Gale.4
The completion of the human genome project and wide-
spread distribution of genotyping technologies have led to an 
enormous number of studies devoted to associating inherited 
gene polymorphisms with various diseases. Single nucleotide 
polymorphisms may result in amino acid substitutions alter-
ing protein function or splicing, and they can also change the 
structure of enhancer sequences during splicing5 and affect 
mRNA stability.6 Single nucleotide polymorphisms may 
alter transcription factor binding motifs, change the efficacy 
of enhancer or repressor elements,7 and alter the structure of 
translation initiation codons that may lead to downregulation 
of wild-type transcripts.8 Gene polymorphisms located in 
leucine-rich repeats constituting ectodomains of many pattern 
recognition receptors may affect the ability of these receptors 
to bind pathogens they normally recognize,9 single nucleotide 
polymorphisms in transmembrane domains can lead to defects 
of intracellular receptor transport that prevent receptors local-
izing to the cell membrane,10 and, finally, polymorphisms in the 
cytosolic domains may result in altered interactions with adaptor 
proteins or in disrupted receptor dimerization. Therefore, there 
are many avenues by which single nucleotide polymorphisms 
may alter pattern recognition receptor expression and activity. 
Because pattern recognition receptors recognize a number of 
oncogenic infectious agents and launch an immune response 
against them, inherited variation in their structure may modu-
late cancer risk and, possibly, influence cancer   progression. In 
addition, pattern recognition receptors bind a lot of endogenous 
ligands,1–4 so polymorphisms of genes encoding them can affect 
risk and/or progression of some autoimmune disorders and, 
consequently, cancer risk and/or progression, given that there is 
a fundamental and epidemiological association between many 
autoimmune diseases and cancer risk.
The problem
Although there are a lot of studies investigating the asso-
ciation between single nucleotide polymorphisms in genes 
encoding Toll-like receptors and NOD-like receptors and 
the risk and features of cancer progression, there is an 
almost complete absence of articles analyzing the correla-
tion between polymorphisms of genes encoding C-type 
lectin receptors and RIG-I-like receptors and cancer risk or 
progression. This can be explained by the fact that the first 
wave of studies devoted to the association of polymorphisms 
of genes encoding Toll-like receptors and NOD-like recep-
tors with cancer risk appeared only in 2004, and the number 
of such papers was relatively small until 2008. In addition, 
known hypotheses about the infectious agents causing human 
cancer and their recognition by pattern recognition receptors 
suggested that Toll-like receptors and NOD-like receptors 
should play a major role in the immune response against 
biological carcinogens. However, more recent findings con-
cerning specific potentially carcinogenic ligands of C-type 
lectin receptors and RIG-I-like receptors were only obtained 
in the last few years,3,4 so there has not been enough time as 
yet to conduct comprehensive investigations between single 
nucleotide polymorphisms of genes encoding C-type lectin 
receptors and RIG-I-like receptors and cancer risk.
However, there is some evidence supporting the hypoth-
esis that inherited features of C-type lectin receptor and 
RIG-I-like receptor structure can be associated with increased 
cancer risk.
First premise: specific ligands
Certain C-type lectin receptors and RIG-I-like receptors 
recognize PAMPs of oncogenic infectious agents.3,4,11,12
C-type lectin receptors:
•	 MRC1 (CD206, CLEC13D, mannose receptor) and 
PAMPs of Mycobacterium tuberculosis, Klebsiella pneu-
moniae, Streptococcus pneumoniae, Candida albicans, 
human immunodeficiency virus type-1 (HIV-1)
•	 CD207 (CLEC4K, langerin) and PAMPs of Candida spp, 
HIV-1
•	 LY75 (CD205, CLEC13B, DEC-205) and PAMPs of 
HIV-1
•	 CD209 (CLEC4L, DC-SIGN) and PAMPs of Mycobac-
terium spp, Schistosoma mansoni, C. albicans, HCV, 
HIV-1, cytomegalovirus
•	 CLEC7A (Dectin-1) and PAMPs of Mycobacterium spp
•	 CLEC1B (CLEC-2) and PAMPs of HIV-1
•	 CLEC6A (CLEC4N, Dectin-2) and PAMPs of M. 
tuberculosis, C. albicans, Paracoccidioides brasiliensis, 
Histoplasma capsulatum
•	 CLEC4E (Mincle) and PAMPs of M. tuberculosis and 
C. albicans
•	 CLEC4A (DCIR) and PAMPs of HIV-1
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RIG-I-like receptors:
•	 RIG-I and PAMPs of Epstein–Barr virus and hepatitis C 
virus
On the basis of known associations between inherited 
structural variations in Toll-like receptors and NOD-like 
receptors and cancer risk,1,2 and according to data about 
cancer types caused by carcinogenic infectious agents,11,12 
it is possible to suggest that risk of lung cancer may be modu-
lated by polymorphisms of the MRC1, CD209, CLEC7A, 
CLEC6A, and CLEC4E genes, oral cancer risk by single 
nucleotide polymorphisms of the MRC1, CD207, CD209, 
CLEC6A, and CLEC4E genes, risk of glioblastoma and 
colorectal cancer by polymorphisms of the CD209 gene, 
hepatocellular carcinoma risk by polymorphisms of the 
CD209 and RIG-I genes, and risk of lymphoma, multiple 
myeloma, nasopharyngeal carcinoma, and esophageal and 
gastric cancer by single nucleotide polymorphisms of the 
RIG-I gene. In addition, single nucleotide polymorphisms 
of MRC1, CD207, LY75, CD209, CLEC1B, and CLEC4A 
genes may correlate with cancer types associated with 
HIV-1 infection.
Second premise: polymorphisms 
affecting function
Certain polymorphisms of genes indicated above may have 
functional consequences on the molecular level that can 
lead to association of such single nucleotide polymorphisms 
with risk or progression of some diseases that may modu-
late cancer risk, so these gene polymorphisms may affect 
cancer risk indirectly. In addition, polymorphisms of these 
genes correlating with diseases that are not related to can-
cer risk may also be useful in oncogenomics because they 
may have functional consequences at the molecular level as 
well, although they have not been investigated in relation 
to association with cancer risk or progression.
For instance, it was suggested that variant alleles of 
MRC1 rs2477637, rs2253120, rs2477664, rs692527, 
rs1926736, and rs691005 gene polymorphisms are associ-
ated with development of asthma13 (eg, variant A allele of 
rs1926736 was connected with decreased asthma risk). In 
addition, Alter et al14 found that the variant A allele (S396) of 
rs1926736 (G396S) polymorphism is associated with a lower 
leprosy risk and, conversely, G allele (G396) correlates with 
increased risk of this disease. Interestingly, G396 did not 
influence leprosy risk in combination with T399 and L407 
(amino acids resulting from variant alleles of rs2478577 and 
rs2437257, respectively).14 The authors noted that all three 
of these MRC1 gene single nucleotide polymorphisms map 
to the second C-type lectin domain (CTLD2) of the MRC1 
protein, with their in vitro results suggesting that a direct 
interaction between CTLD2 and an accessory receptor mol-
ecule is necessary in order for microbial ligand recognition 
to occur.14 It is logical to propose that such interaction would 
be sensitive to G396 only in the context of the A399-F407 
haplotype, and not in the context of the T399-L407 haplo-
type.14 Thus, rs1926736 may have substantial functional 
consequences at the molecular level, but this depends on 
its relationship with other single nucleotide polymorphisms 
in the same exon. Finally, Hattori et al15 showed that a 
variant allele of rs691005 polymorphism, located within 
the 3′ untranslated region of the MRC1 gene, is associated 
with a higher risk of sarcoidosis. Because of its location, 
it is feasible that this single nucleotide polymorphism may 
alter the regulatory binding sequence and influence mRNA 
expression.15
The only study investigating the association of poly-
morphisms of genes encoding C-type lectin receptors and 
RIG-I-like receptors with cancer risk is a study by Xu et al.16 
They investigated single nucleotide polymorphisms of 
the CD209 gene and found that the GG genotype of the 
rs2287886, AA genotype of the −939 promoter polymor-
phism, and the G allele of the rs735239 single nucleotide 
polymorphism were connected with higher nasopharyngeal 
carcinoma risk.16 Polymorphisms in the promoter of the 
CD209 gene and in the CD209 gene were also associated 
with hemorrhage in patients with dengue fever (G allele 
of rs4804803),17,18 modulated tuberculosis risk (G allele of 
rs4804803, A allele of rs735239),19–21 higher celiac disease 
risk in HLA-DQ2-negative cases (G allele of rs4804803),22 
increased ulcerative colitis risk in HLA-DR3-positive 
patients (G allele of rs4804803),23 higher susceptibility 
to cytomegalovirus infection (G allele of rs735240 and 
C allele of rs2287886),24 protection from lung cavitation20 
and fever during tuberculosis25 (GG genotype and G allele 
of rs4804803), decreased HIV-1 infection risk (GG genotype 
of rs4804803),21 accelerated progression to acquired immune 
deficiency syndrome in HIV-1-infected hemophiliacs 
(C allele of rs2287886),26 decreased human T-lymphotropic 
virus type I infection risk (G allele of rs4804803, A allele 
of rs2287886),27 increased severity of liver disease during 
hepatitis C virus infection (G allele of rs4804803),28 and bet-
ter prognosis following severe acute respiratory syndrome 
(G allele of rs4804803).29,30
It was shown that the A allele of the rs4804803 single 
nucleotide polymorphism may increase gene expres-
sion in vitro,17 and, consequently, decreased CD209 gene 
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Table 1 Results of case-control studies investigating the association of polymorphisms of genes encoding C-type lectin receptors, RIG-
I-like receptors, and proteins of their signaling pathways with various diseases, and conditions or features
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
mrc1
Hattori et al13 
Japanese,  
Afro-American  
populations
rs2477637  
(Japanese 0.605–0.645,  
Afro-American  
0.686–0.667)
Asthma Japanese,  
446 cases, 424 controls;  
Afro-American,  
86 cases, 90 controls
Japanese, dominant model 
1.38 (1.02–1.87) Afro-
American, no association
rs2253120  
(Japanese 0.698–0.752,  
Afro-American  
0.663–0.667)
Japanese, additive model 
1.34 (1.07–1.68); dominant 
model 1.55 (1.16–2.09); Afro-
American, no association
rs2477631  
(Japanese 0.484–0.522,  
Afro-American  
0.238–0.267)
Japanese, no association; 
Afro-American, no 
association
rs2477664  
(Japanese 0.509–0.537,  
Afro-American  
0.570–0.572)
Japanese, dominant model 
1.47 (1.06–2.05); Afro-
American, no association
rs692527  
(Japanese 0.521–0.559,  
Afro-American  
0.581–0.389)
Japanese, additive model 
1.25 (1.01–1.55), dominant 
model 1.39 (1.00–1.94); Afro-
American, additive model 
2.17 (1.40–3.37), dominant 
model 2.87 (1.43–5.80) 
recessive model 2.76 
(1.34–5.70)
rs1926736  
(Japanese 0.568–0.522,  
Afro-American  
0.855–0.861)
Japanese, additive model 0.76 
(0.61–0.95), recessive model 
0.61 (0.41–0.89) 0.61; Afro-
American, no association
rs691005  
(Japanese 0.705–0.679,  
Afro-American  
0.401–0.261)
Japanese, no association; 
Afro-American, additive 
model 1.81 (1.16–2.81), 
dominant model 2.43 
(1.32–4.46)
Alter et al14  
vietnamese, Brazilian  
populations
rs1926736 (in vietnamese  
controls 0.35, in Brazilian  
controls 0.32)
Leprosy vietnamese, 704 cases,  
396 controls; Brazilian,  
384 cases, 399 controls
vietnamese, dominant model 
0.76 (0.60–0.96), in the case 
with multibacillary leprosy, 0.71 
(0.51–0.99); Brazilian, additive 
model, for carriers of wild-type 
G allele 1.34 (1.06–1.70), in 
the case with multibacillary 
leprosy, 1.42 (1.05–1.93)
rs2437256 (in vietnamese  
and Brazilian controls 0.21)
No association
rs2478577 (in vietnamese  
controls 0, in Brazilian  
controls 0.21)
No association
rs2437257 (in vietnamese  
controls 0, in Brazilian  
controls 0.21)
For carriers of wild-type G 
allele, dominant model 0.75 
(0.54–1.05); in the case with 
multibacillary leprosy 0.63 
(0.41–0.97)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
Hattori et al15  
Japanese population
rs2477637 (0.412–0.355,  
AG genotype 0.37–0.441,  
GG genotype 0.227–0.134)
Sarcoidosis 181 cases, 424 controls No association
rs2253120 (0.301–0.248,  
AG genotype 0.448–0.325,  
GG genotype 0.077–0.085)
No association
rs2477631 (0.472–0.478,  
AC genotype 0.547–0.479,  
CC genotype 0.199–0.238)
No association
rs2477664 (0.472–0.463,  
AT genotype 0.514–0.455,  
TT genotype 0.215–0.236)
No association
rs692527 (0.492–0.441,  
AG genotype 0.464–0.505,  
GG genotype 0.26–0.189)
No association
rs1926736 (0.453–0.478,  
AG genotype 0.475–0.521,  
AA genotype 0.215–0.217)
No association
rs544995 (0.298–0.295,  
AG genotype 0.431–0.467,  
AA genotype 0.083–0.061)
No association
rs554313 (0.34–0.396,  
AG genotype 0.492–0.462,  
AA genotype 0.094–0.153)
No association
rs691005 (0.376–0.321,  
TC genotype 0.376–0.458,  
CC genotype 0.188–0.092)
Recessive model, 2.53 
(1.47–4.37)
CD209
Xu et al16  
Cantonese population
−116 promoter  
polymorphism  
(0.006 in controls)
NPC 444 cases, 464 controls No association
rs2287886  
(0.275 in controls)
1.42 (1.15–1.74); for 
carriers of AG genotype, 
1.41 (1.05–1.88), for 
carriers of GG genotype, 
2.10 (1.23–3.59)
−190 promoter  
polymorphism  
(in controls 0.003)
No association
rs4804803  
(in controls 0.085)
No association
rs735239  
(in controls 0.154)
1.47 (1.14–1.90); for carriers 
of AG genotype, 1.44 
(1.05–1.98)
rs735240  
(in controls 0.222)
1.43 (1.15–1.79); for carriers 
of AA genotype, 2.52 
(1.29–4.93)
Sakuntabhai et al17  
Thai population
rs4804803 (0.093  
in dengue disease patients,  
0.023 in dengue fever  
patients, 0.116 in dengue  
hemorrhagic fever patients,  
0.104 in controls)
Dengue disease,  
dengue fever, dengue  
hemorrhagic fever
606 cases, 696 controls Risk of hemorrhage during 
dengue fever, 5.84  
(2.77–12.31); risk of dengue 
fever, 0.204; decreased 
CD209 gene expression
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
rs2287886 (0.292  
in dengue disease patients,  
0.266 in dengue fever  
patients, 0.301 in dengue  
hemorrhagic fever patients,  
0.312 in controls)
No association
DCSIGN1.in2+11  
(0.066 in dengue patients,  
0.019 in dengue fever  
patients, 0.081 in dengue  
hemorrhagic fever patients,  
0.083 in controls)
Risk of hemorrhage during  
dengue fever, 4.60  
(2.07–10.22); risk of dengue 
fever, 0.224
DCSIGN1.ex4SF  
(0.007 in dengue patients,  
0.003 in dengue fever  
patients, 0.009 in dengue  
hemorrhagic fever patients,  
0.003 in controls)
No association
DCSIGN1.ex4RPT  
(0.008 in dengue disease  
patients, 0.017 in dengue  
fever patients, 0.005  
in dengue hemorrhagic fever  
patients, 0.006 in controls)
No association
DCSIGN1.in5-178 (0.064  
in dengue disease patients,  
0.017 in dengue fever  
patients, 0.079 in dengue  
hemorrhagic fever patients,  
0.079 in controls)
Risk of hemorrhage during 
dengue fever, 5.30  
(2.25–12.46);  
risk of dengue fever, 0.201
DCSIGN1.ex6TI (0.005  
in dengue disease patients,  
0.003 in dengue fever  
patients, 0.006 in dengue  
hemorrhagic fever patients,  
0.005 in controls)
No association
DCSIGN1.in6-37 (0.049  
in dengue disease patients,  
0.023 in dengue fever  
patients, 0.057 in dengue  
hemorrhagic fever patients,  
0.064 in controls)
Risk of hemorrhage during 
dengue fever, 2.56  
(1.19–5.52); risk of dengue 
fever, 0.371
DCSIGN1.2281 (0.391  
in dengue disease patients,  
0.42 in dengue fever  
patients, 0.38 in dengue  
hemorrhagic fever patients,  
0.344 in controls)
No association
DCSIGN1.3197 (0.112  
in dengue disease patients,  
0.09 in dengue fever  
patients, 0.119 in dengue  
hemorrhagic fever patients,  
0.122 in controls)
No association
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
DCSIGN1.3852 (0.243  
in dengue disease patients,  
0.24 in dengue fever  
patients, 0.244 in dengue  
hemorrhagic fever patients,  
0.267 in controls)
No association
Wang et al18  
Taiwanese population
rs4804803 (0.084  
in dengue patients, 0.054  
in dengue fever patients,  
0.122 in dengue hemorrhagic  
fever cases, 0.028 in other  
non-dengue febrile illness  
cases, 0.038 in controls)
Dengue disease,  
dengue fever, dengue  
hemorrhagic fever
176 dengue fever cases,  
135 dengue hemorrhagic  
fever cases, 143 patients  
with other non-dengue  
febrile illnesses,  
120 controls
Risk of dengue infection, 
2.34 (1.14–4.83); risk of 
dengue hemorrhagic fever, 
3.57 (1.67–7.63); risk of 
hemorrhage during dengue 
fever, 2.44 (1.36–4.40); 
increased levels of TNF-α, 
IL-12p40, IP-10
Barreiro et al19  
South African  
population
rs2048022 (0,434–0.483) Tuberculosis 351 cases, 360 controls No association
rs1380229 (0.361–0.384) No association
rs650389 (0.152–0.195) No association
rs870384 (0.483–0.468) No association
rs695982 (0.321–0.277) No association
rs708682 (0.118–0.123) No association
rs715774 (0.143–0.161) No association
rs1433456 (0.199–0.197) No association
rs807131 (0.355–0.339) No association
rs11672183 (0.12–0.117) No association
rs2024628 (0.422–0.465) No association
rs1028184 (0.342–0.39) No association
rs2056773 (0.395–0.371) No association
rs1479067 (0.259–0.284) No association
rs327747 (0.258–0.292) No association
rs12665321 (0.142–0.129) No association
rs1566838 (0.465–0.458) No association
rs12785524 (0.39–0.424) No association
rs975423 (0.351–0.378) No association
rs914904 (0.292–0.282) No association
rs876287 (0.413–0.409) No association
rs1582598 (0.275–0.265) No association
rs1364198 (0.252–0.227) No association
rs739259 (0.361–0.39) No association
rs169479 (0.133–0.115) No association
rs4804803 (0.454–0.402) 1.48 (1.08–2.02)
rs735239 (0.089–0.141) For carriers of A allele, 1.85 
(1.29–2.66)
rs735240 (0.283–0.313) No association
rs2287886 (0.271–0.288) No association
vannberg et al20  
Gambian, Guinean,  
Guinea-Bissauan,  
Malawian populations
rs4804803 (in Gambian  
population 0.48–0.54,  
in Guinean population  
0.489–0.47, in Guinea- 
Bissauan population  
0.475–0.504, in Malawian  
population 0.352–0.364)
Tuberculosis Gambian: 678 cases,  
327 controls Guinean:  
151 cases, 180 controls  
Guinea-Bissauan:  
162 cases, 141 controls  
Malawian: 244 cases,  
295 controls
For Gambian population, 
0.75 (0.61–0.94); overall, 0.86 
(0.77–0.96); for cavitating 
tuberculosis, 0.42 (0.27–0.65)
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
Selvaraj et al21  
South Indian  
population
rs4804803 (0.181–0.223) Tuberculosis, HIv 238 HIv cases,  
107 HIv+ and  
tuberculosis cases,  
157 controls
For carriers of GG genotype, 
risk of tuberculosis among 
HIv-infected patients, 9.8 
(2.2–44.3)
rs2287886 (0.471–0.468) No association
rs7252229 (0.105–0.101) No association
rs1544767 (0.105–0.108) No association
Nunez et al22  
Spanish population
rs4804803 (0.23–0.21) Celiac disease 103 cases, 312 controls For carriers of GG genotype; 
for HLA-DQ2(−)-individuals 
compared with HLA-DQ2(+) 
individuals and controls, 3.73 
(1.18–11.03)
Nunez et al23  
Spanish population
rs4804803 (0.25 in Crohn’s  
disease patients, 0.22  
in ulcerative colitis patients,  
0.22 in controls)
Crohn’s disease,  
ulcerative colitis
515 Crohn’s disease  
cases, 497 ulcerative  
colitis cases, 731 controls
Risk of ulcerative colitis in 
HLA-DR3-positive patients 
1.77 (1.04–3.02)
Mezger et al24  
European population
rs2287886 Human CMv  
reactivation and disease  
after allogeneic stem  
cell transplantation
70 patients with human  
CMv reactivation,  
59 patients with human  
CMv disease, 65 controls
Risk of human CMv disease, 
1.88 (0.91–3.87)
rs735240 Risk of human CMv 
reactivation, 2.41 (1.22–4.75); 
risk of human CMv disease, 
2.01 (1.05–3.86)
Zheng et al25  
Chinese population
rs4804803 (0.061–0.073) Tuberculosis 237 cases, 244 controls 0.209 (0.058–0.758)
rs735239 (0.207–0.234) No association
Koizumi et al26  
Japanese population
rs2287886 AIDS progression 104 HIv-1-positive  
Japanese hemophiliacs
Risk of accelerated  
AIDS progression:  
1.95 (1.039–3.677)
rs4804803 No association
Kashima et al27  
Mixed population  
from different  
continents
rs2287886 (0.594–0.795) HLTv-1-infection 66 cases, 33 controls For carriers of A allele: Risk 
of HTLv-1-infection: 0.3758 
(0.1954–0.7229)  
For carriers of AA genotype: 
Risk of HTLv-1-infection: 
0.1116 (0.02168–0.5745)
−201 promoter  
polymorphism (0.038–0.016)
No association
−332 promoter  
polymorphism (0.03–0)
No association
rs4804803 (0.144–0.297) For carriers of A allele: Risk 
of HTLv-1-infection: 2.511 
(1.218–5.179)
Ryan et al28  
Irish population
rs4804803 (0.25–0.19) HCv infection 131 cases, 79 controls Increased risk of advanced 
liver disease
Chan et al29  
Hong Kong  
population
rs4804803 SARS 585 cases with lower  
LDH level, 96 cases  
with higher LDH level
Risk of higher LDH level 
during SARS, 0.41   (0.20–0.86);   
decreased expression of 
CD209 gene; Sp1 and AP2 
proteins bind more effectively 
to G allele of rs4804803
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
Chan et al30  
Hong Kong  
population
rs4804803 SARS 824 cases, 471 controls Risk of higher LDH level 
during SARS, 0.41 (0.20–0.86)
CLEC7A (Dectin-1)
Plantinga et al31
Dutch population
rs16910526 (0.078–0.076) Rheumatoid arthritis 262 cases, 284 controls Diminished TNF-α and 
IL-1β production in cells 
from homozygous and 
heterozygous individuals; the 
TLR2/Dectin-1 synergism 
was reduced in cells isolated 
from heterozygous and 
homozygous subjects
Cunha et al32  
Italian population
rs16910526 Invasive aspergillosis 205 cases  
with hematopoietic  
stem cell transplantation
Risk of invasive aspergillosis 
after hematopoietic stem cell 
transplantation, polymorphic 
donor + wild-type recipient, 
2.50 (1.00–6.53) Polymorphic 
donor + polymorphic 
recipient: 3.89 (1.51–9.99)  
Unstimulated CD14-
positive monocytes from 
polymorphic persons 
display a decreased surface 
expression of Dectin 1 in 
response to β-glucan or 
A conidia, PBMCs from 
heterozygous persons 
showed decreased 
production of IL-1β, IL-6, 
IL-10, IL-17A, and IFN-γ
Chai et al33  
Dutch and Flemish  
population
rs16910526 (0.19 in patients  
without hematopoietic  
transplantation with invasive  
aspergillosis, 0.077  
in controls, 0.07 in patients  
with transplantation  
[with and without invasive  
aspergillosis])
Invasive aspergillosis 71 cases with invasive  
aspergillosis after 
hematopoietic stem cell  
transplantation, 21 cases  
with invasive aspergillosis  
without transplantation,  
108 controls with  
transplantation
Increased risk of invasive 
aspergillosis in patients 
without hematopoietic 
transplantation PBMCs 
from variant homozygous 
persons had reduced 
proinflammatory TNF-α and 
IL-6 production in response 
to heat-killed Aspergillus 
fumigatus hyphae, Candida 
albicans blastoconidia, and live 
A. fumigatus conidia;  monocyte-
derived macrophages from 
polymorphic individuals 
had deficient expression 
of the Dectin 1 receptor; 
stimulation using β-glucan 
failed to generate a TNF-α 
response in the Dectin 
1-deficient monocyte-derived 
macrophages from variant 
homozygotes
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
Plantinga et al34  
Dutch population
rs16910526 (0.106–0.138) Colonization with  
Candida spp
142 cases  
with hematopoietic  
stem cell transplantation,  
138 controls
Risk of Candida spp 
colonization, 12.0 
(2.5–57.1); risk of Candida 
spp colonization after 
transplantation, 15.5 
(1.9–125.6); monocytes from 
the variant homozygous 
individuals exhibited no 
Dectin 1 expression on the 
cell surface, whereas cells 
from heterozygous individuals 
had intermediate cell surface 
expression; IL-1β induction 
by C. albicans was lower 
in cells from individuals 
bearing the polymorphism; 
no possibility to amplify 
TLR2 signaling by Dectin 1 in 
cells isolated from variant 
homozygous individuals
Plantinga et al35  
East African  
population
I223S Oropharyngeal  
candidiasis
225 cases with HIv IFN-γ production capacity 
and ability to bind zymosan 
was markedly lower in cells 
from subjects bearing the 
polymorphism
RIG-I
Ovsyannikova et al38  
US population
rs10813821 Cytokine immune  
response in healthy  
children following  
rubella vaccination
738 cases Increased level of IFN-γ
rs9650702 Increased level of IFN-γ and 
decreased level of GM-CSF
rs626214 Increased level of IFN-γ
rs592515 Increased level of IFN-γ and 
TNF-α
rs6476363 Decreased level of TNF-α
rs3739674 Decreased level of TNF-α
rs10813829 Decreased level of TNF-α
rs4633144 Decreased level of TNF-α
rs3824456 Increased level of TNF-α
rs10813831 Decreased level of GM-CSF 
and IL-6
Ovsyannikova et al39  
US population
rs10813831 Cytokine immune  
response in healthy  
children following  
rubella vaccination
738 cases Decreased rubella-specific 
antibody response (median 
antibody level)
rs669260 Increased rubella-specific 
antibody response
Hu et al40
US population
rs10813831 Cytokine immune  
response to Newcastle  
disease
130 cases Increased gene expression in 
Newcastle disease virus-
infected cells
rs12006123 No association
(Continued)
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Table 1 (Continued)
Reference,  
population
SNP number, variant  
allele frequency  
in cases and controls
Disease or condition Sample size OR and 95% CI for 
carriers of variant allele 
(only positive or negative 
statistically significant 
results)
MAVS/VISA/IPS-1
Pothlichet et al50  
Mixed population
rs11905552 (0.126–0.102  
in Afro-American  
population, 0.013–0  
in European-American  
population)
SLE 520 cases, 510 controls For Afro-American 
population, probability of 
absence of anti-RNA-binding 
protein autoantibodies 
2.6 (1.5–4.6); decreased 
level of NF-κB, IL-8, IFN-β 
and RANTES; significantly 
reduced interaction of MAvS 
with TRAF3
Q198K (0.187–0.2  
in African-American  
population, 0.128–0.155  
in European-American  
population)
No association
Liu et al51  
Chinese population
rs17857295 (0.496–0.468) SLE 123 cases, 95 controls Risk of SLE-related renal 
nephritis, 0.58 [0.34–0.97]
rs2326369 (0.272–0.232) Risk of SLE-related arthritis, 
0.27 (0.09–0.80)
rs7262903 (0.098–0.147) No association
rs7269320 (0.098–0.11) Association with patients 
positive for SLE-related 
arthritis, 0.45 (0.21–0.94); 
association with patients 
positive for SLE-related renal 
nephritis, 0.42 (0.18–0.98); 
association with patients 
negative for SLE-related 
oral ulcer, 0.40 (0.18–0.89); 
association with patients 
negative for SLE-related 
photosensitivity, 0.38 
(0.17–0.89)
Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MRC, mannose receptor C; CD, cluster of differentiation; NPC, nasopharyngeal 
carcinoma; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; TNF, tumor necrosis factor; IL, interleukin; IP, interferon-gamma 
inducible protein 10; HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency virus; HTLV, human T-cell lymphotropic virus; HCV, hepatitis C virus; SARS, 
severe acute respiratory syndrome; LDH, lactate dehydrogenase; Sp, specificity protein; AP, activator protein; CLEC, C-type lectin domain, the next number is the family 
number 7, the next letter is the letter of family member; TLR, toll-like receptor; PBMC, peripheral blood mononuclear cell; IFN, interferon; RIG-I, retinoic acid-inducible 
gene I; GM-CSF, granulocyte-macrophage colony-stimulating factor; MAvS/vISA/IPS-1, mitochondrial antiviral signaling protein/virus-induced signaling adapter/induced by 
phosphate starvation-1; NF-κB, necrosis factor kappa B; RANTES, regulated on activation, normal T-cell expressed and secreted; TRAF, TNF receptor-associated factor; 
SLE, systemic lupus erythematosus.
expression in subjects with the G allele may result in an 
impaired immune response against hepatitis C virus,28   
M. tuberculosis,19,21 and bacteria potentially causing celiac 
disease22 and ulcerative colitis,23 that elevates the risk of 
diseases caused by these infectious agents. Such a decreased 
immune response may protect from hemorrhage during den-
gue fever,17 from lung cavitation,20 from fever during tubercu-
losis,25 and from lung injury during severe acute respiratory 
syndrome29,30 as a result of less cytokine production and 
diminished activation of immune cells. However, from the 
point of view of   Vannberg et al,20 conversely, lower CD209 
gene expression as a consequence of G allele of rs4804803 
polymorphism may protect against tuberculosis because of 
decreased production of proinflammatory cytokines such 
as interleukin-4. Further fundamental, translational, and 
clinical studies are necessary to clarify these discrepancies. 
Nevertheless, although there are a number of reasons for 
the discrepancies between studies devoted to the association 
between CD209 single nucleotide polymorphisms and devel-
opment of tuberculosis, but confounding host, bacterial, and 
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environmental factors between different study populations 
should be taken into account. In addition, Mezger et al24 
demonstrated that alleles of rs735240 and rs2287886 poly-
morphisms may also influence CD209 gene expression and 
thus affect transcription factor binding.
In relation to the CLEC7A (Dectin-1) gene, it was also 
found that a variant allele of rs16910526 polymorphism 
is associated with impaired cytokine production by mac-
rophages31,32 and with a defective response to Aspergillus 
and Candida invasion.33,34 The variant S form of I223S 
polymorphism was characterized by a lower capacity of the 
receptor to bind zymosan.35
Among polymorphisms of genes encoding RIG-I-
like receptors, RIG-I single nucleotide polymorphisms 
are the most investigated. Pothlichet et al36 conducted a 
comprehensive study investigating the functional conse-
quences of rs36055726 (P229fs) and rs11795404 (S183I) 
  polymorphisms. They found that the variant allele of 
rs36055726 results in a truncated constitutively active RIG-I 
(that leads to permanent production of proinflammatory 
mediators, particularly   antiviral), and, conversely, the vari-
ant allele of rs11795404 induces an abortive conformation 
of RIG-I, causing formation of unintended stable complexes 
between CARD modules of RIG-I and between RIG-I and 
its downstream adapter protein, MAVS, rendering RIG-I 
incapable of downstream signaling and further cytokine 
synthesis.36 Moreover, Shigemoto et al identified a variant 
of rs11795404 as a loss-of-function allele.37   Ovsyannikova 
et al38,39 showed that a minor allele of rs10813831 poly-
morphism is associated with a decrease in the rubella 
virus-specific granulocyte-macrophage colony-stimulating 
factor/interleukin-6/IgG response, whilst a variant allele of 
rs3824456 is connected with an increase in the rubella virus-
specific tumor necrosis factor alpha response, and a variant 
allele of rs669260 correlates with an increase in the rubella-
specific antibody level. Hu et al40 discovered that a variant 
allele of rs10813831 polymorphism leads to increased gene 
expression and, consequently, cytokine production due to an 
amino acid substitution in the CARD domain of RIG-I that 
results in functional alteration of this RIG-I-like receptor.
There are also a lot of studies investigating the role of 
IFIH1/MDA5 (the gene encoding MDA5 protein that is also a 
RIG-I-like receptor) single nucleotide polymorphisms in the 
etiology of autoimmune diseases, but almost all of them are 
devoted to type 1 diabetes and multiple sclerosis, and data 
about the association of these diseases with cancer risk are 
conflicting, in that some studies showed an increased risk in 
patients with type 1 diabetes and multiple sclerosis,41,42 and 
in other investigations no connection or decreased risk of 
cancer has been observed.43–49 Taking into account that there 
are no carcinogenic infectious agents recognizing MDA5, it 
does not seem to be prudent to investigate IFIH1/MDA5 gene 
polymorphisms from the oncogenomic point of view.
Table  2  Polymorphisms  of  genes  encoding  C-type  lectin 
receptors,  RIG-I-like  receptors,  and  proteins  of  their  specific 
signaling pathways that have known functional consequences and 
may be relevant to oncogenomics
Gene Single nucleotide polymorphism
Genes encoding CLRs
MRC1 rs1926736*
rs2478577*
rs2437257*
rs691005*
rs2477664
rs692527
rs2253120
rs2477637
CD209 rs2287886*
rs735239*
rs4804803*
rs735240*
CLEC7A rs16910526*
I223S
Genes encoding RLRs
RIG-I rs36055726*
rs11795404*
rs10813831*
rs3824456
rs669260
rs9650702
rs626214
rs592515
rs6476363
rs3739674
rs10813829
rs4633144
rs10813821
Genes encoding proteins of CLR and RLR intracellular signaling pathways
MAVS/VISA/IPS-1 rs11905552
rs17857295
rs2326369
rs7269320
Note: *Single nucleotide polymorphisms that can be valued as the most promising 
for further oncogenomic investigation.
Abbreviations: PRRs, pattern recognition receptors; PAMPs, pathogen-associated 
molecular patterns; DAMPs, damage-associated molecular patterns; TLRs,   Toll-like 
receptors; NLRs, NOD-like receptors; CLRs, C-type lectin receptors; RLRs,   RIG-I-like 
receptors; SNPs, single nucleotide polymorphisms; MRC, mannose receptor C; CD, 
cluster of differentiation; CLEC, C-type lectin domain, the next number is the family 
number 7, the next letter is the letter of family member; HIV, human immunodeficiency 
virus; LY, lymphocyte antigen; DEC-205, dendritic and epithelial cells 205 kDa;   DC-SIGN, 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; HCV, 
hepatitis C virus; CMv, cytomegalovirus; DCIR, dendritic cell immunoreceptor; RIG-I, 
retinoic acid-inducible gene I; EBv, Epstein–Barr virus; CARD, caspase recruitment 
domain; MAvS, mitochondrial antiviral signaling protein; IFIH, interferon induced with 
helicase C domain; MDA, melanoma differentiation-associated gene; vISA,   virus-induced 
signaling adapter; IPS-1, induced by phosphate starvation-1.
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In addition, polymorphisms of genes coding for compo-
nents of the Toll-like receptor signaling pathway may modu-
late cancer risk as single nucleotide polymorphisms of the 
TLR gene family.1 The same statement can be true for C-type 
lectin receptor and RIG-I-like receptor signaling pathways. 
For instance, a variant allele of rs11905552, encoding MAVS/
VISA/IPS-1, a key downstream signaling molecule of RIG-I 
and MDA5, was associated with a particular systemic lupus 
erythematosus phenotype.50 It was found that this single 
nucleotide polymorphism leads to reduced production of type 
I interferon and other proinflammatory mediators, and also 
to the absence of anti-RNA-binding protein autoantibodies.50 
In addition, variant alleles of rs17857295 and rs2326369 
polymorphisms of the MAVS/VISA/IPS-1 gene were associ-
ated with nephritis and arthritis in patients suffering from 
systemic lupus erythematosus.51 A variant allele of another 
single nucleotide polymorphism of this gene, rs7269320, 
showed associations with different clinical characteristics of 
this autoimmune disease.51 All the population case-control 
studies mentioned above are summarized in Table 1.
Conclusion and future directions
All polymorphisms of genes encoding C-type lectin recep-
tors, RIG-I-like receptors, and proteins of their specific sig-
naling pathways that have known functional consequences 
and may be relevant to oncogenomics are summarized 
in Table 2. The fundamental basis for the association of 
the inherited coding variation in genes encoding C-type 
lectin receptors and RIG-I-like receptors with cancer is 
represented by the defects in the immune response (that 
are caused by various single nucleotide polymorphisms) 
against specific carcinogenic infectious agents. Some 
polymorphisms may be valued as the most promising for 
further oncogenomic investigations on the basis of their 
association with cancer risk or because of their substantial 
functional consequences on the molecular level according 
to the following concept:
Gene polymorphism may be included on the short list for 
further oncogenomic studies if:
•	 The single nucleotide polymorphism leads to substan-
tial functional consequences at the molecular level 
(for instance, it strongly affects transcription, splicing, 
translation, stability and transport of pre-mRNA, mRNA, 
noncoding RNA, or protein encoding by the gene, or it 
noticeably influences signaling of synthesized protein)
•	 It is associated with risk of cancer in population studies
•	 It has functional consequences at the molecular level 
and it is strongly associated with a condition that 
significantly increases the risk of cancer (threshold may 
vary for each cancer type) 
The gene polymorphism can be also included on the 
extended list if:
•	 It is characterized by more subtle functional alterations 
in a gene that, nonetheless, result in qualitative or quan-
titative alterations of the encoding protein (or noncoding 
RNA)
•	 It is associated with a condition that substantially 
increases the risk of cancer but has not specifically been 
identified to increase the risk of cancer.
According to this concept, the indicated short list of 
polymorphisms includes rs1926736, rs2478577, rs2437257, 
rs691005 (all located in the MRC1 gene), rs2287886, -939 
promoter polymorphism, rs735239, rs735240, rs4804803 (all 
located in the CD209 gene), rs16910526 (CLEC7A gene), 
and rs36055726, rs11795404, rs10813831 (all located in the 
RIG-I gene). Other polymorphisms mentioned in this article 
may be added to the extended list for further investigations. 
Polymorphisms with known functional effects (rs1926736, 
rs2437257, rs691005, rs2287886, rs735240, rs4804803, 
rs16910526) were associated with relatively significant 
modulation of risk of diseases (as shown in Table 1) which 
is logical and demonstrates the correctness of the studies in 
which functional consequences of such single nucleotide 
polymorphisms were analyzed. There are still no compre-
hensive functional investigations for other single nucleotide 
polymorphisms correlated with risk of disease, so it is dif-
ficult to conclude which of them have independent signifi-
cance, and which of them are just in linkage disequilibrium 
with truly functional variants.
In addition, PAMPs of specific infectious agents recog-
nized by each C-type lectin receptor or RIG-I-like receptor 
define cancer types which can be primarily associated with 
inherited structural variation in the receptors discussed 
earlier. Furthermore, if a single nucleotide polymorphism 
of a gene encoding a specific C-type lectin receptor or RIG-
I-like receptor is associated with risk or progression features 
of certain malignancies, polymorphisms in genes encoding 
specific signaling molecules constituting pathways of these 
receptors should correlate with similar neoplasms, if they 
have substantial functional consequences at the molecular 
level. The issue of an association of single nucleotide poly-
morphisms of genes encoding C-type lectin receptors, RIG-
I-like receptors, and proteins of pattern recognition receptor 
pathways with various features of cancer progression is open, 
and only further population studies would be likely to give 
a definite answer.
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Reasons for discrepancies in different investigations 
analyzing the association of polymorphisms in genes encod-
ing C-type lectin receptors, RIG-I-like receptors, and the 
proteins of their signaling pathways with various aspects 
of cancer development may include confounding host, 
bacterial, or environmental factors in different ethnicities 
modulating penetrance of variant alleles and affecting the 
risk of conditions increasing cancer risk (such as autoim-
mune diseases, precancerous gastric lesions, tuberculosis, 
recurrent pneumonia), different bacterial impact on the eti-
ology of such conditions in different populations (that will 
be reflected in different features of C-type lectin receptor/ 
RIG-I-like receptor-mediated immune response because of 
specific C-type lectin receptor/RIG-I-like receptor-ligand 
interaction), differences in sample size, in clinicopathologi-
cal characteristics between study samples, in prevalence of 
infectious agents in case and control groups, diagnostics, 
stratification, genotyping methods, and chance.
Another interesting issue is that associations between 
single nucleotide polymorphisms of genes encoding C-type 
lectin receptors and RIG-I-like receptors and cancer risk 
can be skewed by differences between cohorts in various 
immune responses and infections that may not influence 
cancer development. The problem is that the design in an 
epidemiological study having a large sample is very seldom 
ideal. Stratification by status of chronic infection is rather 
difficult because of their extreme diversity and because of the 
very high cost of such testing. Stratification by an immune 
response is even more complex because of innumerable 
peculiarities in functioning of the immune system. Therefore, 
if the study has a perfect funding source, stratification by 
infection status can be possible, but stratification by immune 
response status will be far from ideal.
Unfortunately, to the best of the authors’ knowledge, 
no genome-wide association studies of the connection 
between polymorphisms of genes encoding the C-type 
lectin receptor and RIG-I-like receptors and cancer risk or 
progression have been performed, and this can be explained 
by the relative newness of the problem or perhaps by another 
unknown reason.
Summing up, polymorphisms of genes encoding C-type 
lectin receptors, RIG-I-like receptors, and proteins of their 
signaling pathways may be promising targets for oncogenom-
ics and possibly could be used in programs of cancer preven-
tion and early cancer diagnostics in the future. Population and 
further fundamental studies devoted to their association with 
cancer risk of progression should shed light on this issue.
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